News - Boehringer Ingelheim


Current filters:

Boehringer Ingelheim

Popular Filters

154 to 167 of 167 results

AIDS drugmakers’ charity programs fail patients, yet provide millions in tax breaks to industry, AHF accuses, but applauds Boehringer


The USA-based AIDS Healthcare Foundation (AHF) is, in its own words, “blowing the whistle”…

Boehringer IngelheimFinancialGilead SciencesNorth AmericaPharmaceuticalPricing

Now Boehringer and Bristol-Myers in talks to join Medicines Patent Pool for HIV medicines


Following swiftly on its first deal with a pharmaceutical company, the Medicines Patent Pool, which was…

Anti-viralsBoehringer IngelheimBristol-Myers SquibbGlobalPatentsPharmaceutical

EU Commission closes antitrust case in Boehringer/Almirall dispute over COPD drugs


The European Commission has closed an antitrust investigation into allegations by Spain’s largest…

AlmirallBoehringer IngelheimEuropeLegalPatentsPharmaceuticalRespiratory and PulmonarySpiriva

Pfizer and B-MS’ blood thinner Eliquis better than expected in Ph III trial


US drug majors Pfizer (NYSE: PFE) and Bristol-Myers Squibb (NYSE: BMY) had a significant boost when they…

BayerBoehringer IngelheimBristol-Myers SquibbCardio-vascularEliquisPfizerPharmaceuticalPradaxaResearchXarelto

Boehringer gains global rights to Zealand’s diabetes/obesity compounds in 376 million-euro deal


German independent drug major Boehringer Ingelheim has signed an exclusive global licence and collaboration…

Boehringer IngelheimDiabetesLicensingMetabolicsPharmaceuticalResearchZealand Pharma

Boehringer Ingelheim and Lilly begin US roll-out of diabetes drug Tradjenta


German independent drug major Boehringer Ingelheim and USA-based Eli Lilly (NYSE: LLY) announced yesterday…

Boehringer IngelheimDiabetesEli LillyMarkets & MarketingNorth AmericaPharmaceuticalTradjenta

Judge vacates Amylin injunction against Eli Lilly; latter updates Humalog label


It was a good news day for US drug major Eli Lilly (NYSE: LLY) yesterday, as the firm received approval…

AmylinBoehringer IngelheimDiabetesEli LillyExenatide InjectionHumalogLegallinagliptinNorth AmericaPharmaceuticalRegulation

Investment in oncology drug development remains strong, with 133 firm initiating late-stage trials


Trials targeting non-small cell lung cancer, breast cancer and multiple hematological cancers are amongst…

Boehringer IngelheimMerck KGaANovartisOncologyPharmaceuticalResearchRoche

Changing the Indian culture in reporting adverse drug reactions


Adverse drug reactions (ADRs) are the sixth global leading cause of death among hospitalized patients…

Asia-PacificBoehringer IngelheimPharmaceuticalRegulationResearch

Amylin wins first round in squabble with Lilly over diabetes link with Boehringer


In an initial win for US biotech firm Amylin Pharmaceuticals (Nasdaq: AMLN), the US District Court for…

AmylinBoehringer IngelheimDiabetesEli LillyExenatide InjectionLegallinagliptinNorth AmericaPharmaceuticalTradjenta

Amylin sues Eli Lilly, alleging anti-competitive activity


San Diego, USA-based Amylin Pharmaceuticals (Nasdaq: AMLN) has filed a law suit against drug major Eli…

AmylinBoehringer IngelheimByettaDiabetesEli LillyLegallinagliptinPharmaceuticalTradjenta

US FDA clears Boehringer and Lilly’s diabetes drug Tradjenta


The US Food and Drug Administration has approved Tradjenta (linagliptin), for use along with diet and…

Boehringer IngelheimDiabetesEli LillylinagliptinNorth AmericaPharmaceuticalRegulationTradjenta

154 to 167 of 167 results

Back to top